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Abstract
Mesenchymal stem cells (MSCs) are advanced therapy medicinal products used 
in cell therapy applications. Several MSC products have already advanced to phase 
III clinical testing and market approval. The manufacturing of MSCs must comply 
with good manufacturing practice (GMP) from phase I in Europe and phase II 
in the US, but there are several unique challenges when cells are the therapeutic 
product. Any GMP-compliant process for the production of MSCs must include 
the expansion of cells in vitro to achieve a sufficient therapeutic quantity while 
maintaining high cell quality and potency. The process must also allow the efficient 
harvest of anchorage-dependent cells and account for the influence of shear stress 
and other factors, especially during scale-up. Bioreactors are necessary to produce 
clinical batches of MSCs, and bioprocess development must therefore consider this 
specialized environment. For the last 10 years, we have investigated bioprocess 
development as a means to produce high-quality MSCs. More recently, we have also 
used bioreactors for the cocultivation of stem cells with other adult cells and for the 
production of MSC-derived extracellular vesicles. This review discusses the state of 
the art in bioprocess development for the GMP-compliant manufacture of human 
MSCs as products for stem cell therapy.
Keywords: bioreactors, quality-by-design, critical process parameters,  
stem cell potency, standardization
1. Manufacturing cell therapy products
Cell therapy is a growing clinical research and healthcare sector in which living 
cells are introduced into a patient in an attempt to ameliorate or cure a disease. 
Stem cell therapy is one of the most promising fields within this sector because 
the introduced cells have the capacity to differentiate, allowing the repopulation 
of diseased organs with healthy cells, or to allow even complete organ regenera-
tion. This chapter will focus on one specific type of stem cell (MSCs), which are 
variously defined as mesenchymal stem cells, mesenchymal stromal cells, or 
(most recently) medicinal signaling cells [1]. These various definitions reflect the 
controversial origin and functionality of MSCs and uncertainty about their clinical 
potential [2, 3]. Following encouraging initial results, the unclear or disappointing 
outcomes of some MSC clinical trials have clouded the picture [4], but the pioneers 
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of this approach still regard MSCs as a promising therapeutic option [5]. One of the 
key issues in the deployment of MSCs is ensuring they are safe and effective, which 
requires a well-characterized manufacturing process.
In order to provide enough MSCs for cell therapy, donor cells must be isolated 
from tissue and then expanded in vitro to reach a population of 1–9 × 108 cells, 
which is the typical dose for adult treatment [6]. The success or failure of MSC 
therapy depends on this in vitro expansion process, which was first studied in detail 
following the failure of the MSC product Prochymal in phase III trials for graft 
versus host disease (GvHD) [4], whereas a similar product succeeded in phase 
II. One reason proposed for the contrasting outcomes of each trial was the substan-
tial differences in the MSC expansion step at the manufacturing scale, highlighting 
the specialized and complex nature of MSCs [4].
1.1 Definition of MSCs and current approved products
MSCs are classified as advanced therapeutic medicinal products (ATMPs) 
under regulations in Europe and the US. Many countries follow the regulations laid 
down by the US Food and Drug Administration (FDA), which defines MSCs as cell 
therapy products, whereas the European Medicines Agency (EMA) defines MSCs 
as cell-based medicinal products and distinguishes between somatic cell therapy 
medicinal products (SCTMPs) and tissue engineered products (TEPs) [7]. This 
means that clinical studies and drug approval are covered by a specific regulatory 
framework applied at the national or regional level. Manufacturing must therefore 
be compliant with good manufacturing practice (GMP) regulations that have been 
tailored for ATMPs, following strict criteria for product specification and release 
for clinical use. However, the regulatory framework for MSC manufacturing is 
confounded by ambiguous product definitions reflecting regional differences in 
the way the regulations are implemented. For example, the EMA requires GMP 
compliance and manufacturing authorization for phase I material, whereas the 
FDA does not apply this requirement until phases II and III, and in Canada, GMP 
compliance is not strictly required at any phase [8]. Even so, various MSC products 
have been manufactured under these different regulatory jurisdictions and have 
proceeded through clinical development, in some cases gaining market authoriza-
tion from the local regulatory agency [9]. Most of these products are allogenic, 
which means that MSCs from one or more healthy donors are expanded, processed, 
and stored and then applied to patients as an off-the-shelf product (Table 1). In 
2016, the allogenic MSC product TEMCELL (developed by Mesoblast) was licensed 
to JCR Pharmaceuticals, which received market authorization in Japan under a 
fast-track protocol for patients with steroid-refractory acute GvHD. Mesoblast 
also conducted a phase III trial with this product in the US, involving 60 patients 
of the same indication, achieving the primary endpoints (NCT02336230). In 2018, 
ALOFISEL (Takeda Pharma), an expanded allogenic adipose-derived MSC product, 
was approved by the EMA to treat complex perianal fistula in patients with Crohn’s 
disease. This was supported by a placebo-controlled trial involving 212 patients 
[10]. Stempeucel (Stempeutics), an expanded allogenic MSC product, received 
market authorization from the Drug Controller General of India to treat limb isch-
emia in patients with Buerger’s disease. However, it is limited to 200 patients on a 
cost-recovery basis, and a postmarket surveillance study is required. Ninety patients 
have already received an injection of this MSC product in a phase II trial, achieving 
a significantly better outcome than standard care [11]. CARTISTEM (Medipost) 
is an allogenic culture-expanded umbilical cord blood MSC product to treat knee 
articular cartilage defects in patients with osteoarthritis, grade IV, and following 
approval for the South Korean market in 2012, its clinical outcomes have remained 
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stable over 7 years of follow-up studies [12]. Several autologous MSC products 
have also been approved in South Korea, meaning that the MSCs are isolated from 
the patient’s own tissue and then manipulated/expanded in a patented process 
and re-injected into the patient 4–6 weeks later. NEURONATA-R (Corestem) and 
Cellgram-AMI (Pharmicell) are autologous bone marrow-derived MSCs indicated 
for amyotrophic lateral sclerosis and acute myocardial infarction, respectively. Two 
other MSC products derived from adipose-tissue have been approved (Anterogen): 
a mixture of autologous adipose-derived MSCs with other cells for subcutaneous 
tissue defects (Queencell) and a pure adipose-derived MSC product for Crohn’s 
fistula treatment (Cupistem) [9]. NEURONATA-R has been designated as an orphan 
drug by the EMA and FDA.
This brief survey of the market shows that the promise of MSC therapy is 
materializing, with positive efficacy data in controlled clinical trials followed by 
regulatory approval for a small number of products.
1.2 The therapeutic properties of MSCs
Although MSCs have been used in cell therapy applications for many years, the 
fundamental biology of these cells and their precise therapeutic properties are not 
fully understood. MSCs were initially isolated from bone marrow (bm-MSCs) based 
on their plastic adherence, but today they are usually isolated from adipose tissue 
(ad-MSCs) or umbilical cord blood (uc-MSCs), which are more accessible [13]. MSCs 
are also found in various other adult, fetal, and perinatal tissues [14]. Regardless 
of their origin, MSCs are heterogeneous and polyclonal cells, with at least three 
Product 1 Product 2
Exemplary products ALOFISEL Queencell
Indication Crohn’s disease, perianal fistula Regeneration of subcutaneous 
tissue
Patients per year 23,000 (in EU)* n.d.
Cell type Allogenic MSCs Autologous, patient-specific 
MSCs
Cell source Adipose tissue Adipose tissue
Cells per dose 1.2 × 108 MSCs 7 × 107**
Therapeutic relevant cell 
properties***
Anti-inflammation, immune 
modulation
Regeneration, anti-apoptosis
Manufacturing type Bulk manufacturing Patient-specific batch
Batch size Large (min. 100–1000 doses per 
batch)
Small (1 dose per batch)
Scalability of production Scale up Scale out, several batches in 
parallel
Product storage Frozen, off-the-shelf No storage
Stability under storage Stable >6 month, frozen Fresh, stable max. 24 hours
*0.003% of all citizens (741 million) in Europe are putative patients.
**Stromal vascular fraction contains MSCs and other cell types such as preadipocytes, endothelial progenitor cells, 
pericytes, mast cells, and fibroblast.
***Following both products have different critical quality attributes (CQAs) and the manufacturing processes have 
different critical process parameters (CPPs).
n.d. not determined.
Table 1. 
Indication and properties of MSC products impact their manufacturing.
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subpopulations defined based on morphology. Type I MSCs are spindle-shaped pro-
liferating cells resembling fibroblasts. Type II MSCs are large, flat, epithelial-like cells, 
which are more senescent than type I cells and feature visible cytoskeletal structures 
and granules. Finally, type III MSCs are small round cells with a high capacity for 
self-renewal [15]. The heterogeneity of MSCs can be considered beneficial in that it 
ensures that some therapeutically active cells are present, but it reduces the maximum 
potential efficacy because some of the cells are inactive. However, even monoclonal 
MSCs become heterogeneous during expansion [16].
Despite the heterogeneity described above, the International Society of Cell 
Therapy has published a set of minimal criteria that must be met before cells can 
be defined as MSCs. Such cells must (i) show plastic adherence; (ii) be able to 
differentiate into cartilage, bone, and fat tissue in vitro; and (iii) express the cluster 
of differentiation (CD) surface markers CD73, CD90, and CD105, but not CD11b, 
CD14, CD19, CD34, CD45, or HLA-DR [17]. However, this standard set of markers 
does not distinguish between MSCs and fibroblasts or nonstem mesenchymal cells 
[18]. Several other markers may be more specific but are only detected in certain 
MSC isolates or subpopulations. These include stage-specific embryonic antigen-4 
(SSEA-4), stem cell antigen-1 (SCA1), nestin, CD44, CD146, CD166, and CD271 
[19]. A unique MSC surface marker has yet to be identified.
It is important to note that MSCs cannot be defined merely as a collection of 
surface markers because this says nothing about their therapeutic effect (Figure 1). 
Initially, the therapeutic potential of MSCs was believed to reflect their ability to 
migrate into damaged tissues, differentiate in situ, and replace damaged or dead 
cells. However, although MSCs can differentiate in vitro, their ability to differenti-
ate in vivo has never been confirmed [20]. Current opinion is that MSCs migrate 
to injury sites and secrete chemoattractants that recruit tissue-specific stem cells, 
Figure 1. 
Properties of MSCs and their mode of action. MSCs modulate the host immune systems, e.g., by secreting 
various trophic factors. Thereby, they reduce inflammation, promote neoangiogenesis, and prevent apoptosis 
and fibrosis. Further, they stimulate local stem cells to develop new tissue. TSG-6, tumor necrosis factor-
inducible gene 6 protein also known as TNF-stimulated gene 6 protein; STC1, stanniocalcin 1; IL-4/6/10, 
interleukins 4, 6 and 10; CCL20, macrophage inflammatory protein-3; IDO, indoleamine 2,3-dioxygenase; 
PGE2, prostaglandin E2; VEGF, vascular endothelial growth factor; FGF-2, basic fibroblast growth  
factor; HGF, hepatocyte growth factor; IGF-1, insulin-like growth factor 1; CXCL12, stromal cell-derived 
factor 1; MMP1/2/9, matrix metalloproteinase-1/2/9.
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which in turn generate new tissues or exert positive immunomodulatory effects [1]. 
The MSC secretome comprises a pool of cytokines, chemokines, growth factors, 
and extracellular vesicles (carrying proteins, lipids, and various forms of RNA). 
This secretome differs widely among MSC isolates and subpopulations and can be 
used to functionally distinguish between several MSC types (e.g., type I, II, and III 
cells), revealing that the self-renewable type III cells are therapeutically the most 
effective [16].
The immunomodulatory properties of MSCs and their secretion of anti-
inflammatory molecules and extracellular vesicles are an important therapeutic 
functionality [14]. MSCs are therefore logical candidates for the treatment of 
immune disorders, including GvHD, inflammatory bowel disease, multiple sclero-
sis, rheumatoid arthritis, and diabetes [21]. MSCs also secrete peptides and factors 
that promote the regeneration of damaged tissue by stimulating cell proliferation 
and migration, promoting angiogenesis, and suppressing apoptosis and fibrosis 
[14]. The regenerative capacity of MSCs has been used to treat Alzheimer’s disease, 
bone and cartilage diseases, diabetes, myocardial infarction, and osteoarthritis 
[22]. Another advantage of MSCs is that they do not form teratomas in vivo, which 
ensures an outstanding clinical safety profile. Human MSCs achieve senescence 
without evidence of transformation into tumor cells [23].
1.3 The critical quality attributes of MSCs
The biological complexity and heterogeneity of MSCs hamper the translation of 
laboratory-scale experiments into industrial processes for cost-effective and reliable 
manufacturing. This can be addressed by developing MSC manufacturing processes 
that adhere to quality-by-design (QbD) principles [24]. QbD provides a rational 
framework and integrates scientific knowledge and risk analysis into process 
development. It is guided by a thorough understanding of the fundamental biology 
and engineering principles underlying an MSC product and its production process. 
QbD begins with a description of the desired product quality characteristics, known 
as the quality target product profile (QTPP). This is used to identify critical qual-
ity attributes (CQAs), which are physical, chemical, and biological attributes that 
define the quality of the product. The QTPP for MSCs describes properties such 
as identity, purity, and potency, which will be unique for each MSC product and 
dependent on the therapeutic indication.
1.3.1 Identity
For MSCs, identity often means the cell phenotype, but as discussed above, there 
is no agreement on a single definition. Identity is often demonstrated by confirm-
ing a typical morphology and/or karyotype [25] and by detecting the presence or 
absence of surface markers. The minimal criteria for MSCs (see above) have led 
to a misconception that cells meeting these criteria are equivalent in identity and 
therapeutic functionality. In polyclonal MSC populations, the presence of multiple 
cell types can be a clinical benefit as stated above [26], and this should be reflected 
in the identity attributes.
1.3.2 Potency
The functionality and potency of MSCs are closely linked to their therapeutic effi-
cacy and thus the clinical outcome, but potency is used to demonstrate manufactur-
ing consistency for batch release so a measurable property is required. Viability can 
fulfill the role of a potency indicator because only living cells can act as a therapeutic 
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entity. Potency can also be measured using in vitro functional assays that determine 
MSC activity directly or via an indirect metric that correlates to MSC activity in vivo. 
An assay that measures differentiation potential is only appropriate to describe MSC 
potency if the therapeutic aim involves engraftment of the cells or tissue formation 
(notwithstanding the controversy over the assumption that MSCs differentiate in 
vivo, as discussed above). The FDA mandates that potency is measured using quanti-
tative biological assays [27], so the standard approach is to differentiate MSCs in vitro 
by cultivating them in differentiation medium and then testing them after 21 days 
[17]. Staining for differentiation markers is nonquantitative, so alternative methods 
such as postdifferentiation RNA or protein analysis [28, 29], or the online monitoring 
of differentiation by Raman spectroscopy [30], are more suitable.
If the therapeutic effect of MSCs is conferred by the secretome, then the 
differentiation potential may not be the primary determinant of potency. The 
profile of secreted factors would be a more appropriate measure, and this could be 
determined by multiplex enzyme-linked immunosorbent assays (ELISAs) or mass 
spectroscopy [31]. However, a clear link between the secretome profile and in vivo 
efficacy must be established, so that animal models or cell-based assays can be used 
to determine the limits of the relevant factors. This is a typical way to move from a 
complex and highly variable in vivo assay to a multiassay approach combining the 
quantification of viability, target-specific cytotoxicity or cytokine release, sur-
rogate biomarkers (morphological phenotype or released factors that correlate with 
function), bioactivity (e.g., presentation of surface markers), cell-based assays, and 
genomic, transcriptomic, and proteomic profiles [32].
1.3.3 Sterility and purity
Impurities are unwanted components from within the process, whereas con-
taminants come from outside the process. Impurities during MSC manufacturing 
include unwanted cell types, particles (e.g., residual microcarriers, or plastics 
and fibers from manufacturing equipment and materials), or components of 
culture medium. Contaminants include bacteria, fungi, viruses, endotoxins, and 
mycoplasma. The heterogeneity of MSCs makes it difficult to detect unwanted cell 
types. MSC preparations should ideally be pure, but fibroblasts are often present as 
impurities. Cell-specific sorting based on the marker CD166 (which is expressed at 
higher levels on MSCs) and CD9 (which is expressed at higher levels on fibroblasts) 
may help to achieve sufficient purity [33]. In other cases, it may be sufficient if most 
of the cells in the final product (>98%) fulfill the ISCT minimal criteria based on 
MSC surface markers. All other impurities and contaminants must be measured 
and the maximum residual levels must be defined to ensure safety and efficacy. A 
final sterilization step is not possible when the product is living cells, so the entire 
MSC production process must be carried out under aseptic conditions.
From the QTPP list, CQAs must be identified, which directly influence the 
safety and efficacy of the MSC product. This means that a risk assessment is car-
ried out to reduce the QTPP list to the most influential attributes based on impact 
and certainty. According to ICHQ8, a CQA is “A physical, chemical, biological, or 
microbiological property or characteristic that should be within an appropriate limit, 
range, or distribution to ensure the desired product quality.” Therefore, every process 
parameter “whose variability has an impact on a CQA” is a critical process parameter 
(CPP) that “should be monitored or controlled to ensure that the process produces the 
desired quality.” There is no precise delimitation of the degree of impact required to 
define a CPP, so the broad definition of a CPP is generally divided into parameters 
that have a substantial impact on the CQAs and those with minimal or zero impact. 
Each process step has multiple CPPs. For example, during the in vitro expansion 
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step, CPPs can be directly associated with the MSCs (e.g., cell density and cell age) 
or raw material attributes (e.g., medium, serum, and growth factors) or operational 
features of the culture vessel/bioreactor system (e.g., pH, temperature, dissolved 
oxygen, and agitation). The effect of each CPP on the CQAs must be quantified 
in a design space. With an appropriate control strategy, the CPPs are kept in their 
normal operational range, which ensures the production of high-quality MSCs 
that meet all the required CQAs. Based on the heterogeneity and the complexity of 
MSCs, each MSC product can have unique CQAs and the corresponding CPPs must 
be identified case by case.
2. Expansion of human MSCs in vitro
Therapeutic applications of MSCs require at least 1 × 108 cells per dose, which is 
many more than can be isolated by tissue aspiration. All MSC production processes 
must therefore include an in vitro expansion. Having generated or isolated the start-
ing cell population, in vitro expansion is followed by harvest, concentration, purifi-
cation, formulation, fill and finish, storage, and shipping. The manufacturing steps 
of MSCs are therefore similar to the production of recombinant proteins, but MSCs 
are more challenging due to the variability of the starting material, the complexity 
of living cells as a product, an incomplete understanding of their mechanism of 
action, and the inherent difficulties encountered during product characterization.
2.1 CPPs that affect MSC manufacturing
The properties of MSCs are strongly influenced by the environment because 
MSCs in nature interact with surrounding cells and tissues, with the extracellular 
matrix and with various bioactive molecules. Even in an artificial environment like 
a bioreactor or T-flask, MSCs are very sensitive to their environment, and the most 
influential factors give rise to CPPs. By identifying CPPs that affect MSC quality, 
the process can be designed to favor the recovery of MSCs with specific phenotypes 
of interest, in this case those with the greatest therapeutic efficacy [34, 35]. The 
CPPs affecting MSC quality are discussed in more detail below.
2.1.1 Cell density and age
During MSC isolation, the seeding density is important because all sources 
contain different quantities of MSCs. For example, only 1 in 100,000 bone marrow 
cells is an MSC, whereas in adipose tissue, the ratio is nearer to 1 in 100 [36]. If 
plastic adherence is selected as a strategy for MSC isolation, the number of adherent 
cells therefore differs according to the source if a similar number of tissue cells are 
seeded. Standardization during this step can be achieved by isolating MSCs using a 
strategy of surface marker sorting, allowing a defined number of cells to be seeded 
into the culture vessel. The seeding density selected for the in vitro expansion step 
is a CPP. MSCs can be seeded at a very low density (50–100 cells per cm2) and will 
proliferate until they achieve confluence. This corresponds to a high expansion 
factor, but the process takes a long time and requires more rounds of cell division 
for each seeded cell, so the cells experience significant aging [37]. The aging of 
MSCs during expansion is a problem, because older cells lose competence to behave 
as stem cells and have a tendency to enter senescence or even to undergo transfor-
mation. The manufacturing of Prochymal provided a clear example of this issue: 
10,000 or more doses were manufactured from one donor, and the corresponding 
expansion stress led to replicative senescence, in which the cells retained a typical 
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MSC surface marker profile but lost functionality [4]. Aging MSCs are more 
likely to activate a senescence-associated secretory phenotype and produce pro-
inflammatory cytokines such as IL-1, IL-6, and IL-8, which inhibit the regenerative 
process. The duration of in vitro expansion must be considered not only because 
of senescence, but also due to the phenomenon of clonal impoverishment. MSCs 
are polyclonal, but prolonged expansion favors the growth of specific cell types or 
clones. Depending on the expansion time and expansion factor, the cell mixtures 
may completely differ in phenotype and also in potency. Therefore, although a high 
expansion factor in a short process time is desirable to achieve high product yields, 
in vitro expansion should never change the properties of MSCs to the extent that it 
compromises their functionality and potency.
2.1.2 Culture medium
Several basal media have been shown to influence MSC expansion and 
potency, including Dulbecco’s modified Eagle’s medium (DMEM), Iscove’s modi-
fied Dulbecco’s medium (IMDM), and MEM alpha (αMEM) [37]. One of the key 
components of these media is glucose, which is the main carbon source for MSCs. 
Glucose may be provided at physiological concentrations (1 g/L) or higher (up to 
4.5 g/L), the latter variously described as having a negative effect on MSC prolifera-
tion and growth factor secretion [38] or no effect at all [39]. Glutamine as a second 
carbon source is present at concentrations of 2–4 mM and appears essential for 
MSC growth [40], but its impact on MSC properties is complex, with contradictory 
results [41–43]. Glutamine is unstable at 37°C and spontaneously degrades to form 
ammonia. GlutaMAX (dipeptide Ala-Gln) is recommended instead of glutamine to 
promote MSC expansion [44]. Lactate and ammonia are the most abundant waste 
products formed by MSCs, and both therefore have the potential to inhibit growth. 
It therefore follows that glucose, glutamine, lactate, and ammonia levels should 
be considered as CPPs for the production of MSCs. Several other amino acids may 
also be relevant, given that the amino acid metabolism of MSCs differs from that of 
commercial cell lines such as Chinese hamster ovary (CHO) cells [42].
Basal media formulations must be supplemented to achieve MSC expansion. 
The most important supplement is fetal calf serum (FCS), which is added to a final 
concentration of 5–20%. FCS strongly influences MSC growth and phenotype, but 
the specific effectors are unknown because the composition of FCS is variable and 
lot-dependent [45]. The use of FCS for the manufacture of clinical MSC products is 
discouraged nowadays, in line with the drive to eliminate all raw materials of animal 
origin. The complex, uncertain, and variable composition of FCS also makes it dif-
ficult to validate for GMP-compliant processes. Finally, the manufacturing process 
must accommodate steps to eliminate FCS from the final product to avoid potential 
immunogenicity and allergenicity [46]. FCS can be replaced with human serum and 
its derivatives, such as human platelet lysate, which promotes MSC growth [47]. 
However, the same lot-dependent quality issues described above for FCS also apply 
to human serum [48]. The most acceptable alternative is serum-free or prefer-
ably chemically-defined medium, the latter not only serum-free but also lacking 
any hydrolysates or supplements of unknown composition. MSCs grow well in 
several commercial serum-free media, including BD Mosaic MSC Serum-free (BD 
Biosciences), RoosterNourish (Rooster Bio), Mesencult-XF (Stemcell Technologies), 
StemPro MSC SFM Xeno-Free (Invitrogen), TheraPEAK MSCGM-CD (Lonza), and 
PPRF-msc6, STK1 and STK2 (Abion) [49]. Growth in chemically-defined medium 
has also been demonstrated [50]. However, although MSCs showed excellent growth 
in these serum-free media, they reached senescence earlier, and there were changes 
in morphology, surface marker profiles, and potency [51]. This does not mean that 
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serum-free and chemically-defined media should be avoided-it is still better to use 
these media for MSC expansion in order to meet GMP requirements-but further 
investigations are required to optimize the media composition. The development 
of serum-free media is mainly driven by companies, which tend not to disclose the 
precise composition, making it difficult for other researchers to build on the results. 
In serum-free and defined media, supplemental growth factors such as FGF2 and 
PDGF are needed to stimulate MSC proliferation, but they also influence MSC 
potency [18]. Accordingly, chemically-defined media would be preferable for the in 
vitro expansion of MSCs, but growth factor concentrations are important CPPs that 
affect MSC identity and potency and must be carefully controlled.
2.1.3 Conditions in the culture vessel
MSCs are aerobic cells and any culture vessel must therefore ensure an adequate 
supply of oxygen. However, the oxygen saturation in standard T-flasks (21% O2) is 
far removed from nature (5–7% O2) [34]. MSCs therefore tend to be oversaturated 
with oxygen, which can increase the concentration of damaging reactive oxygen 
species (ROS). Several studies have confirmed that hypoxia enhances MSC pro-
liferation, stabilizes their cell fate, and prevents apoptosis by reducing the levels 
of caspase-3 [52]. However, rather than imposing hypoxia by preconditioning the 
cells, it may be better to impose hypoxia during the entire expansion phase, because 
this mimics their natural niche [53].
In addition to oxygen saturation, temperature and pH are CPPs in every process 
and can be monitored and controlled very easily. Typically, in vitro expansion is 
carried out at 37°C and neutral pH (7.2–7.4). Expansion at lower temperatures can be 
advantageous under certain circumstances because this reduces stress (ROS produc-
tion and frequency of apoptosis) and may yield more potent MSCs. Although the 
expansion of MSCs has been achieved in the pH range 7.5–8.3 [54], it is unclear how 
significant variations in pH influence MSC metabolism and whether this affects the 
secretome. The optimal temperature and pH must be evaluated for each MSC product.
Other CPPs include the parameters grouped under the term hydrodynamics, refer-
ring to the potential impact of aeration and agitation. Aeration is required to supply 
oxygen to the MSCs, but as well as affecting the oxygen saturation, it also generates 
forces that cause physical stress. In T-flasks, aeration is achieved by the diffusion of 
oxygen through the surface of the medium, whereas bioreactors must be actively 
aerated by, e.g., bubbling gas into the liquid. The bursting gas bubbles (cavitation) 
generate strong forces that can damage cells, although the stress can be reduced by 
controlling the bubble size [55]. Agitation in bioreactors is generally achieved with 
impellers, which help to disperse gas (and therefore contribute to aeration) but also 
maintain a homogenous suspension of cells and nutrients. The creation of a homog-
enous environment is advantageous because it avoids gradients of pH, nutrients, or 
waste products, whose effect on MSCs is unpredictable. Homogenization can also be 
achieved using pumps or is facilitated by air bubbles. Agitation always generates shear 
forces, so it is necessary to balance the homogeneity of the cultivation system and 
the impact of the hydrodynamic forces on the MSCs. Although excessive shear stress 
is detrimental, hydrodynamic forces can also stimulate MSC growth and increase 
potency [43]. For these reasons, the mode and rate of aeration and the method and 
intensity of agitation are CPPs that must be carefully optimized for each process.
2.1.4 Growth surface, cell harvest, and storage
MSCs are anchorage-dependent cells, so the properties of the growth surface 
also have a significant impact on the process and must be investigated and selected 
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carefully. However, unlike the parameters discussed above, the growth surface 
does not have to be monitored or controlled during MSC production, so it falls 
outside the technical definition of a CPP. The expression of certain surface markers 
by MSCs reflects the stiffness of the growth surface, so it is clear that the surface 
affects the phenotype [56]. As stated above, the ability to adhere to plastic surfaces 
is one of the minimal criteria that define MSCs, and tissue-culture plastic is there-
fore the most commonly-used growth surface. Although all commercial tissue-cul-
ture plasticware has a polypropylene base, the surface is often treated differently, 
and this changes the behavior and properties of the adherent MSCs [37]. MSCs 
further grow on other surface materials, e.g., glass [57] or dextran [58]. When MSCs 
are cultivated in serum-free medium, cell growth often requires that the surface is 
coated with further adhesion-promoting factors, such as fibronectin, vitronectin, 
or the peptide RGD.
Given that MSCs are anchorage-dependent cells, the harvesting of cells at the 
end of the in vitro expansion step requires an efficient cell detachment method 
that ideally does not affect functionality or potency. In the laboratory, MSCs can be 
detached from T-flasks by adding trypsin or other proteases, but this nonspecific 
proteolysis can affect cell viability and eliminate some MSC surface markers [59]. 
Proteolytic cleavage is incompatible with the larger-scale processes in bioreactors 
because longer incubation times are required for the enzymes to work, and even 
then, the efficiency of cell recovery is low [60]. More importantly, any negative 
effects of the enzymatic treatment on cell viability and potency are amplified by the 
longer exposure time, which can inhibit MSC differentiation [61]. These issues can 
be addressed by adjusting the hydrodynamic conditions to favor cell detachment 
after limited enzymatic treatment [62]. Alternatively, enzymatic treatment can be 
circumvented completely by promoting cell detachment using dissolvable growth 
surfaces [63] or thermosensitive surfaces that release cells following a temperature 
shift [64, 65]. However, unlike enzymatic treatments, these novel surfaces do not 
break direct cell-cell bonds and may be unsuitable if single cell is required. The 
formation of aggregates can be minimized by carefully monitoring the cell density 
and selecting a harvest point that favors the recovery of single cell, but this must 
be balanced against the efficiency of expansion given the need to harvest at lower 
cell densities. The so-called harvest problem, balancing the efficient release of cells 
against the recovery of cells with desirable properties, has yet to be solved. This 
highlights the importance of well-defined CPPs at the harvesting stage.
All the approved allogenic MSC products described earlier are cryopreserved, 
allowing them to be offered as off-the-shelf products that can be stored until quality 
control and batch release are completed. The use of cryopreserved allogeneic MSCs 
is the only feasible therapeutic strategy for acute tissue injury syndromes such as 
stroke, sepsis, or myocardial infarction, because the patient is likely to die before 
sufficient quantities of autologous MSCs could be prepared. However, cryopreser-
vation and thawing have a massive impact on the potency of MSCs [66]. Indeed, 
even without optimization, fresh MSCs are much more potent than frozen ones 
[35]. A rule of thumb is to freeze the cells slowly (e.g., 1°C/min) but to thaw them 
quickly (e.g., direct transfer from storage to a 37°C water bath). The impact of 
multiple freeze-thaw cycles must be evaluated carefully [67]. The composition of 
the freezing medium is also important because it often contains dimethyl sulfoxide 
(DMSO) and FCS as cryoprotectants, the first being cytotoxic and the second 
undesirable for the reasons already discussed above. Nontoxic alternatives lacking 
DMSO and FCS have been tested and may be more compatible with MSCs intended 
for clinical applications [68–70].
In summary, the expansion of MSCs in bioreactors involves multiple CPPs 
including (i) the source of the initial MSCs before expansion, (ii) the impact of cell 
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density and age, (iii) the effects of the culture medium, (iv) the properties of the 
bioreactor and aeration/agitation systems, and (iv) the method used for cell harvest 
and storage. The impact of these CPPs on the quality of MSCs can only be deter-
mined by designing robust assays for (i) in vitro senescence and genetic stability 
and (ii) relevant disease-specific mechanism of action and potency. It is clear that 
there is no one-size-fits-all MSC expansion process and that unique processes must 
be developed to match different therapeutic objectives. These processes may feature 
distinct CQAs, meaning that the CPPs may also differ on a case-by-case basis.
2.2 MSC manufacturing for clinical trials
For the 989 interventional clinical trials involving MSCs reported thus far 
(www.clinicaltrials.gov, search term: mesenchymal stem cell OR mesenchymal 
stromal cell, 2019/09/27), the MSCs were expanded in vitro and in most cases were 
transfused intravenously at typical doses of 1–2 × 106 cells per kilogram, never 
exceeding 12 × 106 cells/kg [3].
The manufacture of protein therapeutics is almost always carried out in bio-
reactors because they are scalable, controllable via integrated process analytical 
technology, and most process steps can be automated. This is not the case for 
MSC products, and a survey of GMP manufacturing at US academic centers has 
revealed major differences in the various process steps (cell isolation, expansion, 
and characterization). In the context of cell expansion, 80% of the centers surveyed 
above used T-flasks or cell factories, whereas only 20% mainly used bioreactors. 
A broad range of seeding densities was used for cultivation (50–2500 cells/cm2) 
and the cultivation time ranged from 1 to 28+ days. The cultivation medium was 
supplemented with FCS (lot-selected or not) or donor-pooled human platelet lysate 
(in-house product or commercial product) [71]. All of the centers expanded MSCs 
under GMP conditions, but with huge variations in the protocol. The production of 
MSCs in T-flasks is adequate for a small number of patients (30 T-flasks each with 
a growth surface of 175 cm2 would be required per patient, assuming each patient 
is dosed with 416 million cells and the harvesting efficiency is 8 × 104 cells/cm2 
[72]). But for larger clinical trials with >100 patients, the resources required for cell 
culture would become unsupportable (assuming the conditions stated above, a trial 
with 140 patients would require 4200 T-flasks filling 32 standard 160-L incubators 
and 9 full-time personnel to handle the cells). Expansion in T-flasks might also be 
sufficient for autologous cell therapy, given that only a single patient is involved 
and it would not be necessary to produce more than 10 doses. However, even for 
small-scale manufacturing, an automated bioreactor system would offer several 
advantages over manual cultivation. Given that the entire manufacturing process 
must be aseptic, closed bioreactors provide much better insurance against contami-
nation than an open culture system based on T-flaks. For allogenic MSC products, 
where up to 1 million doses are produced per batch, bioreactors are the only feasible 
manufacturing option (Figure 2).
2.3 The expansion of MSCs in bioreactors
When an MSC product advances from research to commercial manufacturing, 
the in vitro expansion process must also change. Research is driven by the freedom 
to test different conditions, but the tests are typically conducted on a small scale. 
In contrast, commercial products must be manufactured using a standardized 
process to ensure robustness, and the scale is generally larger. Bioreactors play a key 
role in large-scale manufacturing because they offer greater traceability due to the 
control and monitoring of CPPs. The expansion of MSCs in bioreactors allows the 
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precise control of the microenvironment, which has a profound influence on cell 
potency and therapeutic efficacy [73, 74]. For example, the dynamic cultivation 
of human MSCs in a bioreactor has been shown to induce the secretion of several 
beneficial growth factors, including BDNF, NGF, VEGF, and IGF-1 [75]. The use 
of bioreactors also means that the in vitro MSC expansion and harvesting steps can 
be automated, which improves the efficiency of both steps and reduces the amount 
of hands-on work. The elimination of operator-related errors and contamination 
risks makes the process more stable, avoiding batch-to-batch variability. Nutrient 
gradients and abrupt fluctuations in pH caused by manual medium exchange are 
also avoided. This enables the production of MSCs with consistent identity and 
potency (CQAs). Many different bioreactor types have been used for the in vitro 
expansion of MSCs, including fixed bed, fluidized bed, and stirred tank reactors, as 
well as newer innovations such as wave reactors, wall-rotating systems, and vertical 
wheel reactors [76]. However, most studies have involved only two types of reactor: 
stirred tank or fixed bed, and these are discussed in more detail below.
Stirred tank reactors are the most widely-used devices for large-scale MSC expan-
sion. They are often used with microcarriers, which are small beads that increase 
the surface area available for cell attachment, although MSCs can also be grown in 
bioreactors as aggregates or spheroids. The expansion of MSCs growing on microcar-
riers is typically a batch-mode manufacturing process because the cells are harvested 
at a predetermined density. However, fed-batch processes involve a smaller inoculum 
(100 cells/cm2, equivalent to five cells per microcarrier) and can thus achieve better 
economy and a higher expansion factor [77, 78]. There should be minimal (if any) 
agitation at the beginning of the expansion phase to allow for cell attachment to 
the microcarriers (if used) or otherwise for the formation of aggregates. However, 
agitation is required following attachment in order to homogenize the suspension 
and avoid the formation of large clumps. As discussed above, agitation is an impor-
tant CPP and the parameters must be optimized based on the unique combination of 
Figure 2. 
Manufacturing of autologous and allogenic MSC products. Autologous MSC products are isolated from the 
patient’s own tissue, whereas for allogenic MSC products a healthy donor from the same specie donates cells. In 
the isolation and expansion, there are few differences between the two types of MSC products. Most common 
sources are bone marrow, adipose tissue, and umbilical cord (blood), all three giving different amount of MSCs. 
The expansion for both MSC product types differs in scale. Storage is only needed for allogenic MSC products. 
If we expect that 0.4 × 106 MSC are isolated per donation and one dose to treat a single patient is about  
120 × 106 MSCs, an expansion factor of at least 300-fold is needed. If more doses should be produced from one 
isolate, e.g., because the patient needs several treatments or in case of allogenic MSC products, the expansion 
factor dramatically increases.
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system properties (e.g., impeller type/speed and microcarrier size/amount) to keep 
microcarriers or aggregates in suspension without causing shear damage, and these 
parameters must be optimized at different manufacturing scales [79].
Fixed bed reactors are also widely used for MSC expansion, and in this case, the 
cells are grown either on macrocarriers or as capsules (500 μm diameter), both of 
which form a stable bed at the reactor base. The production of homogeneous condi-
tions in the bed can be frustrated by the development of channels and gradients 
in the bed, particularly in large-scale systems [80]. The shear forces in fixed bed 
reactors are low (~0.5 × 10−5 N/cm2) and consistent throughout the reactor with no 
peaks near the impeller; the shear forces also remain constant at all scales [81]. The 
in vitro expansion of MSCs has been reported in several types of fixed bed reactors 
[82–85]. One of the major drawbacks of fixed bed and other reactor types compared 
to stirred tank reactors is the challenge of efficient harvesting. For example, in the 
reports above, the recovery of viable cells is rarely better than 70%, so this is a key 
aspect of bioreactor design that remains to be addressed [60, 86].
2.4 Remaining challenges
The earlier sections highlighted several challenges that must be overcome to 
develop robust processes for the expansion of MSCs in bioreactors, which are 
summarized briefly below. Furthermore, our current understanding of the CPPs 
affecting MSC production is rudimentary at best, and more work is required to 
determine the impact of hydrodynamic factors on the CQAs. Precise online moni-
toring tools are needed to control CPPs effectively and to measure their influence 
on cell viability, potency, and secretory profiles. An increase in process understand-
ing will facilitate process modeling, to fulfill the requirements of process analytic 
technology as a prerequisite for GMP manufacturing.
The major challenge for MSC therapy is the development of an in vitro expan-
sion process that mimics the natural MSC niche, but nevertheless allows scaled up 
production for clinical trials without compromising CQAs such as cell functionality 
and potency. The development of a standardized process is frustrated by the het-
erogeneity of MSCs, which are isolated from different donors and different tissues, 
resulting in variable phenotypes and functions. The heterogeneity of primary MSCs 
can be avoided by working instead with induced pluripotent stem cells (iPSCs), 
which can differentiate into MSC-like cells with potent therapeutic properties [87]. 
However, well-controlled in vitro expansion processes in bioreactors can also help to 
reduce the batch-to-batch variation often encountered with MSCs, because param-
eters such as the seeding density, shear stress during cultivation, and cell density at 
harvest can be monitored and controlled effectively.
Polyclonal MSCs often show the most potent therapeutic effects, but clonal 
impoverishment occurs during lengthy expansion phases and this must be 
avoided if potency is compromised. However, even monoclonal MSCs become 
heterogeneous over time, generating subpopulations with different morphologies 
and surface marker profiles. The therapeutic outcome can only be predicted if 
the MSC pool does not change during expansion, and the well-controlled condi-
tions in bioreactors can therefore help to ensure that the cell products remain 
homogeneous.
Ultimately, even bioreactor-based processes for MSC expansion are constrained 
by the inbuilt replication limit of MSCs, which leads to senescence after a certain 
number of generations. Stem cells by definition have an unlimited capacity for self-
renewal, but this property is lost in vitro. The expansion stress that leads to replica-
tive senescence generates MSCs that maintain their marker profiles but nevertheless 
lose functionality and therefore therapeutic potency.
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The production of MSCs with standardized properties would be facilitated by 
the development of standardized validated potency assays so that results obtained 
in different laboratories are truly comparable. The ISCT has taken steps in this 
direction by publishing standards for the harmonization of potency assays. In a 
matrix assay approach, they propose to use quantitative RNA analysis for selected 
gene products, flow cytometry to detect functionally-relevant surface markers, and 
protein-based assays to map the secretome and determine the immunomodulatory 
potency of MSCs [88].
3. Additional processes that require MSCs
MSCs are typically the sole product of any MSC cultivation process, but in some 
applications, the MSCs are used as helper cells to deliver a different product or they 
are used as a vehicle to produce a specific cellular component. In each case, the 
CQAs differ significantly from the standard MSC manufacturing process and other 
CPPs must therefore be considered. We discuss two examples below.
3.1 Production of MSC-derived extracellular vesicles
MSCs are potent therapeutics, but researchers are seeking new ways to achieve 
the same therapeutic effect without the drawbacks associated with MSC manu-
facturing, such as the limited availability of potent cells, the complex transfusion 
process, and the entrapment of MSCs in nontarget organs [89]. As discussed earlier, 
the therapeutic effect of MSCs reflects the secretion of cytokines, growth factors, 
and other paracrine signaling molecules, particularly via the release of extracel-
lular vesicles that interact directly with target cells and deliver their contents into 
the cytosol. The advantage of these vesicles over whole MSCs is their much greater 
stability, which means they can be manufactured, stored, and shipped without 
losing therapeutic efficacy [90, 91].
The large-scale manufacturing of extracellular vesicles requires the cultivation 
of MSCs, which secrete these vesicles directly in the culture medium. Scalable 
production methods are not yet available, and vesicles are currently produced in 
T-flasks or cell factories without process monitoring. Bioreactors could be used to 
scale up production, and given there is no need to harvest the MSCs, it would be 
possible to consider a wider range of bioreactor systems than the relatively narrow 
selection favored for MSC manufacturing. A fixed bed bioreactor has been used for 
the continuous production and harvesting of extracellular vesicles, which increased 
the yield 10-fold compared to T-flasks [92]. Stirred tank reactors with microcarriers 
might also be suitable, but they have not yet been used for vesicle production [57]. 
The cells would be exposed to shear forces caused by the impellers and air bubble 
cavitation, and this may influence vesicle production and potency [93].
The effect of different process parameters on the production of MSC-derived 
extracellular vesicles has been investigated at the laboratory scale. For example, 
hMSCs and their vesicles are primed by hypoxic conditions or changes in medium 
composition, such as the removal of FCS or the addition of priming factors like 
IFNγ and TNFα [34, 35]. The yield of extracellular vesicles can also be increased by 
preparing spheroids that mimic in vivo conditions, for example by laying down an 
extracellular matrix and supplying appropriate signaling molecules [89]. Cell den-
sity, passage number, and cell origin also affect the vesicle yield. The immortalized 
cell line hMSC-TERT is more stable than primary MSCs, but the immortalization 
process has an impact on vesicle production, which must be investigated individu-
ally for each cell line because it is not related to the immortalization method [93].
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There is currently no standardized large-scale production platform for primed 
hMSC-derived vesicles, but even if such a platform existed, a corresponding 
purification process would be required. The laboratory-scale purification of vesicles 
captured from the culture medium is currently based on a combination of ultracen-
trifugation, dead-end filtration, precipitation, and size exclusion chromatography, 
which are difficult to scale up [94, 95]. However, tangential-flow filtration can also 
be used for large-scale purification, washing, and buffer exchange, and this method 
should be investigated in more detail for vesicle purification [94, 96]. Extracellular 
vesicles are even more sensitive to process changes than MSCs, so the influence of 
multiple cell-dependent, culture, and process parameters on the potency of these 
vesicles must be determined.
3.2 Cocultivation of MSCs with other cells
The ability of MSCs to restore the activity of dysfunctional cells in vivo is the 
basis of their therapeutic efficacy, but the same interactions can also be exploited 
in vitro. One key example is the interaction between MSCs and pancreatic beta 
cells, which are widely used for drug screening and cell therapy in the context of 
diabetes. In both applications, large numbers of functional beta cells are required, 
but beta cells rapidly lose their functionality when expanded in vitro. The loss of 
beta cell functionality in vitro can be prevented by cocultivation with MSCs, which 
not only stimulate beta cell proliferation but also enhance their glucose-dependent 
secretion of insulin [97–99].
The major challenge of cocultivation is to balance the demands of two com-
pletely different cell types. In large scales, the distribution of cells becomes hetero-
geneous, which can lead to instability within the bioreactor and lower cell viability. 
A well-balanced and tightly controlled culture environment is needed to stabilize 
large-scale cocultures. Because secreted factors are important for the cocultivation 
of MSCs and beta cells, the hydrodynamic forces in bioreactors, which influence 
the distribution of secreted molecules, must be considered at an early stage [100]. 
Furthermore, the optimal cocultivation ratio of the cells must be determined. 
Established processes can be modified to achieve a new process setup for cocultiva-
tion, but it is often beneficial to separate cell expansion from cocultivation (i.e., 
first expand the pure cultures to generate the cells needed for the coculture and 
then combine them to improve the function of beta cells in a second process step). 
For the expansion step, it can be sufficient to improve the growth of beta cells using 
conditioned medium from the cultivation of MSCs. Alternatively, the expansion 
and functionalization of beta cells can be combined in one process step [101]. The 
CPPs for such a complex process can be difficult to identify, but the CQAs of the 
beta cells are most relevant if the aim of the process is to produce functionalized 
beta cells for drug screening or cell therapy. Even so, the potency of the MSCs must 
not be neglected because they are required to stimulate the beta cells. Accordingly, 
the MSCs must be expanded under controlled and standardized conditions that 
maximize their beneficial impact on beta cells. In the future, cocultivation bioreac-
tor concepts for MSCs and beta cells must be tested to allow the completely aseptic 
expansion and cocultivation of both cell types.
4. Conclusions
MSCs are potent therapeutic agents, but their complexity and environmental 
sensitivity make the GMP-compliant manufacturing of MSC products extremely 
challenging. Given the range of tissue sources, isolation procedures, and expansion 
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protocols, it is unclear whether MSC products are similar enough across manufac-
turing sites and whether results can be considered comparable even within the same 
study. Moreover, the incomplete definition of MSCs makes it difficult to develop 
objective release criteria. These issues strongly argue for the harmonization and 
standardization of MSC manufacturing processes, release criteria, and potency 
assays. The regulatory standards for MSCs are still evolving, and different standards 
apply in different jurisdictions. MSCs are living cells and cannot be held to the same 
standards as chemical entities or biopharmaceuticals, both of which can be tested 
against rigorous and objective quality criteria. The regulations for MSCs should be 
more flexible, acknowledging that each MSC product is developed for a specific 
indication, and unique platform technologies, CQAs, and CPPs may therefore be 
necessary for each manufacturing process. One of the most important platform 
technologies is the use of bioreactors for cell expansion, because this is the only 
current strategy that can bring MSC therapy into routine practice. MSCs can also be 
used as production aids for other products, including beta cells for drug screening 
or diabetes therapy, and novel biological agents such as extracellular vesicles. In the 
future, they could even be used for commodity products such as artificial meat. 
But in all these applications, a robust and scalable manufacturing process will be 
necessary.
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